CJC-1295 + Ipamorelin: The Complete Growth Hormone Stack Guide

CJC-1295 and Ipamorelin are synthetic peptides that work together to stimulate growth hormone (GH) release through complementary mechanisms. CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that signals the pituitary to produce GH, while Ipamorelin is a growth hormone-releasing peptide (GHRP) that enhances this signal by suppressing somatostatin and activating ghrelin receptors. When combined, clinical research shows they can increase GH levels 2- to 10-fold and IGF-1 levels 1.5- to 3-fold compared to baseline—significantly more than either peptide achieves alone due to GHRH-GHRP synergy. Neither peptide is FDA-approved for human use, and the FDA has flagged both as presenting potential safety concerns when compounded.

This guide covers the science behind how these peptides work individually and together, what clinical research has demonstrated, the regulatory landscape as of 2026, and important safety considerations for researchers and clinicians.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before using any peptides. These compounds are not FDA-approved for human use.

What Are CJC-1295 and Ipamorelin?

CJC-1295 and Ipamorelin belong to a class of compounds called growth hormone secretagogues (GHS)—substances that stimulate the body's own production of growth hormone rather than introducing exogenous GH directly.

CJC-1295 (also known as Drug Affinity Complex:Growth Hormone-Releasing Factor or DAC:GRF) is a synthetic analog of natural GHRH. Developed by ConjuChem Biotechnologies, it incorporates four amino acid substitutions at positions 2, 8, 15, and 27 that make it resistant to degradation by dipeptidyl peptidase IV (DPP-IV), an enzyme that rapidly breaks down natural GHRH.

Ipamorelin (development code NNC 26-0161) is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It was developed by Novo Nordisk and represents a more selective evolution of earlier GHRPs like GHRP-6 and GHRP-2.

There are two forms of CJC-1295:

• CJC-1295 with DAC: Contains a Drug Affinity Complex that binds to serum albumin, extending the half-life to 6-8 days
• CJC-1295 without DAC (Modified GRF 1-29 or Mod GRF): Has a half-life of approximately 30 minutes, requiring more frequent administration

How Does CJC-1295 Work?

CJC-1295 mimics the action of natural GHRH by binding to GHRH receptors on somatotroph cells in the anterior pituitary gland. This binding initiates a signaling cascade involving cyclic AMP (cAMP), which ultimately stimulates the synthesis and release of growth hormone.

According to research published in the Journal of Clinical Endocrinology & Metabolism, CJC-1295's key advantages over natural GHRH include:

1. Extended Duration: The DAC technology allows CJC-1295 to form covalent bonds with serum albumin through a Michael addition reaction with cysteine-34. Greater than 90% of administered CJC-1295 becomes albumin-bound within 24 hours, creating a high-molecular-weight complex that resists degradation.

2. Sustained GH Release: In a randomized, placebo-controlled clinical trial, a single subcutaneous injection of CJC-1295 increased mean plasma GH concentrations 2- to 10-fold for 6 days or more.

3. Prolonged IGF-1 Elevation: The same study found IGF-1 levels increased 1.5- to 3-fold and remained elevated for 9-11 days after a single dose. With multiple doses, IGF-1 remained above baseline for up to 28 days.

4. Preserved Pulsatility: Unlike exogenous GH administration, CJC-1295 maintains the natural pulsatile pattern of GH secretion, which may have physiological advantages.

How Does Ipamorelin Work?

Ipamorelin acts through a different pathway than CJC-1295. It binds to the ghrelin receptor (GHSR-1a) on pituitary somatotrophs, stimulating GH release independently of GHRH signaling.

What makes Ipamorelin notable is its selectivity profile. According to foundational research published in the European Journal of Endocrinology, Ipamorelin is "the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH."

Key characteristics from the research:

• GH Potency: In vitro EC50 of 1.3 nmol/L with 85% maximum effectiveness, comparable to GHRP-6
• No ACTH/Cortisol Elevation: Unlike GHRP-2 and GHRP-6, Ipamorelin did not stimulate ACTH or cortisol release—even at doses 200-fold higher than the ED50 for GH release
• No Effect on Other Hormones: Does not affect prolactin, FSH, LH, or TSH levels

This selectivity matters because cortisol elevation can counteract some benefits of GH release and cause unwanted side effects. Ipamorelin's clean profile makes it the preferred GHRP for many researchers.

Why Combine CJC-1295 with Ipamorelin?

The rationale for combining these peptides lies in the synergistic interaction between GHRH and GHRP pathways. Research published in the American Journal of Physiology has extensively documented this phenomenon.

The Science of GHRH-GHRP Synergy

Growth hormone secretion is regulated by three primary signals:

1. GHRH (stimulatory): Signals the pituitary to release GH
2. Somatostatin (inhibitory): Suppresses GH release
3. Ghrelin/GHRP (modulatory): Amplifies GHRH signaling and may inhibit somatostatin

When GHRH and GHRP are administered together, the combined effect exceeds what either achieves alone. Research shows this synergy can amplify GH secretion by approximately 2.2-fold beyond the additive effect of either peptide individually.

According to a study examining GHRH-GHRP interactions in healthy adults:

• Burst Size Amplification: The synergy primarily increases GH secretory-burst size rather than pulse frequency
• Age Effects: Acute synergy was 3-fold greater in young subjects compared to older volunteers
• Gender Differences: Elderly women showed 2.3-fold higher synergy than elderly men

How the Stack Works Together

When CJC-1295 and Ipamorelin are combined:

1. CJC-1295 provides sustained GHRH receptor activation, maintaining elevated baseline signaling
2. Ipamorelin amplifies each GH pulse through ghrelin receptor activation
3. Combined Effect: Research suggests an approximate 7.5-fold increase in GH pulse amplitude compared to placebo
4. Duration Profile: Ipamorelin exhibits earlier onset while CJC-1295 extends the duration of GH-related activity

What Does the Clinical Research Show?

CJC-1295 Clinical Data

The most comprehensive clinical data on CJC-1295 comes from Teichman et al., published in the Journal of Clinical Endocrinology & Metabolism (2006):

Study Design:

• Randomized, placebo-controlled, double-blind trials
• Healthy adults ages 21-61
• Trial durations of 28-49 days
• Subcutaneous administration

Key Findings:

Tolerability: "No serious adverse reactions were reported. CJC-1295 was safe and relatively well tolerated, particularly at doses of 30 or 60 μg/kg."

Ipamorelin Clinical Data

Ipamorelin reached Phase II clinical trials for postoperative ileus (POI) before being discontinued due to lack of efficacy for that specific indication:

Beck et al. POI Trial:

• 114 patients undergoing bowel resection
• Twice daily 0.03 mg/kg ipamorelin vs. placebo
• Primary endpoints (time to first meal, first bowel movement) did not reach statistical significance
• Patients undergoing open laparotomy showed shorter GI recovery times (not statistically significant)

Comparative Potency Data

From swine studies comparing GHRPs:

Ipamorelin shows similar efficacy to GHRP-6 while maintaining its superior selectivity profile.

What Is the FDA Status of These Peptides?

As of 2026, neither CJC-1295 nor Ipamorelin is FDA-approved for any indication.

Current Regulatory Classification

Both peptides have been placed in Category 2 on the FDA's list of "Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks." This classification effectively restricts compounding pharmacies from producing these peptides for human use.

FDA's Stated Concerns:

For CJC-1295, the FDA has flagged:

• Risk of immunogenicity (immune reactions to the peptide)
• Peptide-related impurities
• "Increased heart rate and systemic vasodilatory reaction, including flushing, warmth, and transient hypotension"

For Ipamorelin, the FDA cited:

• Immunogenicity concerns
• The presence of unnatural amino acids complicating characterization
• Serious adverse events including death when administered intravenously (note: standard administration is subcutaneous)

Legal Challenges and Current Status

The Category 2 designation is currently subject to legal challenges. At this writing:

• Multiple compounding pharmacy associations have filed suit
• Enforcement has been suspended pending resolution
• A Pharmacy Compounding Advisory Committee (PCAC) review is expected in July 2026

Researchers should note that "research-grade" peptides sold online are explicitly labeled "not for human consumption" and lack pharmaceutical quality controls.

What Are the Potential Side Effects?

Based on available clinical data, the side effect profile of CJC-1295 and Ipamorelin appears relatively mild, though long-term safety data is limited.

Common Side Effects

Serious Considerations

Contraindications:

• Active cancer or history of cancer (GH can promote cell proliferation)
• Uncontrolled diabetes
• Pregnancy or breastfeeding
• Known hypersensitivity to peptides

Drug Interactions: These peptides may interact with:

• Insulin and diabetes medications
• Thyroid medications
• Corticosteroids
• Testosterone or hCG therapy
• Exogenous growth hormone

Long-Term Unknowns:

• Metabolic effects on insulin sensitivity
• Cardiovascular effects on blood pressure and lipids
• Immune system effects from chronic peptide exposure

Frequently Asked Questions

What is the difference between CJC-1295 with DAC and without DAC?

CJC-1295 with DAC (Drug Affinity Complex) has a half-life of 6-8 days due to albumin binding, requiring once-weekly dosing. CJC-1295 without DAC (Modified GRF 1-29) has a half-life of approximately 30 minutes and typically requires 2-3 daily injections. The non-DAC version more closely mimics natural GHRH pulsatility but requires significantly more frequent administration.

Can CJC-1295 and Ipamorelin cause cancer?

There is no direct evidence that these peptides cause cancer. However, because growth hormone can promote cellular proliferation, the FDA and most clinicians advise against use in anyone with active cancer or a history of cancer. The theoretical concern is that elevated GH/IGF-1 could accelerate the growth of undetected tumors.

How do these peptides compare to direct GH injections?

Unlike exogenous GH, CJC-1295 and Ipamorelin stimulate the body's own GH production while maintaining natural pulsatile secretion patterns. Potential advantages include avoiding supraphysiological GH spikes and preserving negative feedback mechanisms. However, neither approach is FDA-approved for anti-aging or performance enhancement.

Why were these peptides restricted by the FDA?

The FDA cited three primary concerns: immunogenicity (the potential for allergic or immune reactions), challenges with quality control and impurity testing, and limited long-term safety data. For CJC-1295 specifically, cardiovascular effects including transient hypotension were also noted.

Are "research-grade" peptides safe?

Research-grade peptides lack the quality controls of pharmaceutical-grade products. They may contain impurities, incorrect concentrations, or degradation products. The FDA and medical authorities consistently advise against using research-grade peptides for human consumption.

Key Takeaways

• CJC-1295 is a GHRH analog that extends GH elevation for 6+ days per dose through albumin binding (DAC version) or 30 minutes (non-DAC version)
• Ipamorelin is the most selective GHRP, releasing GH without affecting cortisol, ACTH, or other hormones
• Combined, they create synergistic GH release—clinical data suggests up to 7.5-fold increases in GH pulse amplitude
• Neither peptide is FDA-approved for human use; both are currently Category 2 bulk drug substances with compounding restrictions
• Side effects are generally mild (injection site reactions, headaches, water retention) but long-term safety data is lacking
• Anyone considering these peptides should consult with a qualified healthcare provider and understand the regulatory and safety limitations

Sources

• Teichman SL, et al. "Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295." J Clin Endocrinol Metab. 2006
• Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." Eur J Endocrinol. 1998
• Veldhuis JD, et al. "Determinants of GH-releasing hormone and GH-releasing peptide synergy in men." Am J Physiol Endocrinol Metab. 2009
• FDA. "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks." 2026
• Alba M, et al. "Once-daily administration of CJC-1295 normalizes growth in the GHRH knockout mouse." Am J Physiol Endocrinol Metab. 2006